Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Current Assets (2016 - 2025)

Historic Current Assets for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $753.9 million.

  • Ligand Pharmaceuticals' Current Assets rose 14368.11% to $753.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $753.9 million, marking a year-over-year increase of 14368.11%. This contributed to the annual value of $331.6 million for FY2024, which is 3964.55% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Current Assets stood at $753.9 million, which was up 14368.11% from $352.9 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Current Assets ranged from a high of $753.9 million in Q3 2025 and a low of $220.4 million during Q3 2022
  • Moreover, its 5-year median value for Current Assets was $312.3 million (2024), whereas its average is $346.5 million.
  • In the last 5 years, Ligand Pharmaceuticals' Current Assets plummeted by 5242.13% in 2021 and then surged by 14368.11% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Current Assets (Quarter) stood at $464.8 million in 2021, then tumbled by 43.28% to $263.6 million in 2022, then decreased by 9.93% to $237.4 million in 2023, then skyrocketed by 39.65% to $331.6 million in 2024, then surged by 127.39% to $753.9 million in 2025.
  • Its last three reported values are $753.9 million in Q3 2025, $352.9 million for Q2 2025, and $309.3 million during Q1 2025.